Development of enzyme immunoassay of glial fibrillary acidic protein on the basis of recombinant antigen.
Quantitative enzyme immunoassay of glial fibrillary acidic protein of astrocyte intermediate filaments opened new prospects for highly selective diagnosis and monitoring of pathological processes in the CNS. Immunochemical screening of glial fibrillary acidic protein in biological fluids helps to adequately evaluate the permeability of the blood-brain barrier in CNS diseases associated with violation of its functions, such as hypoxic and ischemic disorders, neuroinfections, glial tumors, brain injuries, etc. Wide-scale introduction of enzyme immunoassays into clinical laboratory practice implies the development of biotechnological approaches to the creation of methods for obtaining EIA components. This paper presents a method for creation of a test system for EIA of glial fibrillary acidic protein (GFAP) on the basis of recombinant GFAP and antibodies obtained by immunization with recombinant GFAP. Due to this approach, a highly standardized test system for the analysis of GFAP in human biological fluids was created.